Afghanistan vs Papua New Guinea: Average cost of multi drug-resistant tuberculosis treatment
Afghanistan
1,000 constant 2022 US$
in 2024
Papua New Guinea
953 constant 2022 US$
in 2022
Afghanistan rank
48th
Papua New Guinea rank
51st
Average cost of multi drug-resistant tuberculosis treatment over time
- Afghanistan
- Papua New Guinea
How they compare
Afghanistan currently reports 1,000 constant 2022 US$ against 953 constant 2022 US$ in Papua New Guinea, a difference of 47 constant 2022 US$.
The two have swapped places 3 times across 5 shared years of data; in 2017 it was Papua New Guinea ahead.
Afghanistan ranks 48th and Papua New Guinea ranks 51st of 92 countries.
Across the 2 decades both report, Afghanistan averaged higher in 1 and Papua New Guinea in 1.
Head to head by decade
| Decade | Afghanistan | Papua New Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,450 constant 2022 US$ | 2,096 constant 2022 US$ | 646 constant 2022 US$ | Papua New Guinea |
| 2020s | 1,000 constant 2022 US$ | 871.67 constant 2022 US$ | 128.33 constant 2022 US$ | Afghanistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Afghanistan or Papua New Guinea?
- Afghanistan, at 1,000 constant 2022 US$ against 953 constant 2022 US$ in Papua New Guinea as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Afghanistan and Papua New Guinea?
- 47 constant 2022 US$, with Afghanistan ahead.
- How many years of comparable data are there for Afghanistan and Papua New Guinea?
- 5 years are reported by both, from 2017 to 2022.
- How do Afghanistan and Papua New Guinea rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Afghanistan ranks 48th and Papua New Guinea ranks 51st of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.